Roche Says FDA's Evaluation Of This Columvi Combination For R/R Dlbcl Is Ongoing And A Decision On Approval Is Expected By 20 July 2025

Roche Holding AG RO:

• ROCHE PROVIDES UPDATE ON FDA ADVISORY COMMITTEE MEETING ON COLUMVI COMBINATION FOR PEOPLE WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

• ROCHE HOLDING AG - FDA'S EVALUATION OF THIS COLUMVI COMBINATION FOR R/R DLBCL IS ONGOING AND A DECISION ON APPROVAL IS EXPECTED BY 20 JULY 2025